Novo Nordisk to seek oral sickle cell therapy approval after Phase III victory
Novo Nordisk said it will approach regulators with the data on the SCD therapy in H2 2026.
21 April 2026
21 April 2026
Novo Nordisk said it will approach regulators with the data on the SCD therapy in H2 2026.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.